Fresenius Medical Care AG & Co. KGaA (FMS) – What Are Researchers Saying About This Stock?

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) have received a consensus rating of “Reduce” from the eleven research firms that are currently covering the firm, Marketbeat reports. Four analysts have rated the stock with a sell rating and seven have given a hold rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $23.42.

A number of equities research analysts recently commented on FMS shares. Zacks Research downgraded Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong sell” rating in a report on Thursday, October 15th. Truist Financial reduced their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $25.00 to $24.00 and set a “hold” rating on the stock in a research note on Monday, October 12th. Berenberg Bank set a $24.00 target price on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, September 29th. Citigroup reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th. Finally, Sanford C. Bernstein lifted their price target on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a “market perform” rating in a research report on Thursday, August 6th.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

A number of large investors have recently made changes to their positions in FMS. Pzena Investment Management LLC lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 2.0% during the 1st quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock valued at $339,592,000 after purchasing an additional 299,986 shares in the last quarter. Royal Bank of Canada grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 479.2% in the 1st quarter. Royal Bank of Canada now owns 216,861 shares of the company’s stock valued at $4,893,000 after purchasing an additional 179,418 shares during the period. Assetmark Inc. increased its stake in Fresenius Medical Care AG & Co. KGaA by 190.7% during the 1st quarter. Assetmark Inc. now owns 132,320 shares of the company’s stock worth $2,985,000 after purchasing an additional 86,798 shares in the last quarter. Moran Wealth Management LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 31.5% during the 1st quarter. Moran Wealth Management LLC now owns 347,773 shares of the company’s stock worth $7,846,000 after purchasing an additional 83,311 shares in the last quarter. Finally, Ritholtz Wealth Management increased its stake in Fresenius Medical Care AG & Co. KGaA by 252.7% during the 1st quarter. Ritholtz Wealth Management now owns 84,658 shares of the company’s stock worth $1,910,000 after purchasing an additional 60,652 shares in the last quarter. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of Fresenius Medical Care AG & Co. KGaA stock opened at $22.66 on Tuesday. The firm has a fifty day moving average of $22.46 and a two-hundred day moving average of $22.87. The stock has a market capitalization of $12.17 billion, a price-to-earnings ratio of 11.74, a PEG ratio of 5.27 and a beta of 0.74. Fresenius Medical Care AG & Co. KGaA has a 52 week low of $20.02 and a 52 week high of $27.40. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 1.07.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. The company had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.48 billion. As a group, equities research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 2.24 EPS for the current year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney failure. The company provides dialysis care for patients with end-stage renal disease through a network of outpatient dialysis clinics and other health care facilities.

In addition to operating dialysis centers, Fresenius Medical Care develops and supplies products used in dialysis treatment. Its portfolio includes hemodialysis machines, dialyzers, dialysis solutions, bloodlines, and related medical devices and services.